New Parkinson's drug BIIB094 passes first safety test in small trial
NCT ID NCT03976349
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called BIIB094 in 62 adults with Parkinson's disease. The drug was given as a spinal injection to see if it is safe and how the body processes it. The study included people with and without certain genetic variations. Results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIIB094
What this could lead to
If successful, this could point toward a new treatment option for Parkinson's disease by targeting a genetic pathway.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (62 people) and may not lead to a working treatment. Side effects from the spinal injection are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research
Knoxville, Tennessee, 37920, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital General de Catalunya
Barcelona, Vizcaya, 08195, Spain
-
Inland Northwest Research
Spokane, Washington, 99202, United States
-
Laboratorios de Investigación Biocruces 3., Hospital de Cruces
Barakaldo, Bizkaia, 48903, Spain
-
Montreal Neurological Institute and Hospital
Montreal, Quebec, QC H3A 2B4, Canada
-
Neuro-SysMed Center
Bergen, 5053, Norway
-
Northwestern University PD and Movement Disorders Center
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Queen Square (Neurology) CRF Site Institute of Neurology & the National Hospital for Neurology and Neurosurgery UCLH
London, WC1N 3BG, United Kingdom
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
-
Research Site
Toronto, Ontario, Canada
-
Research Site
Seville, Spain
-
Sourasky Medical Center
Tel Aviv, 64239, Israel
-
St. Olav University Hospital
Trondheim, 7030, Norway
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19107, United States